VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Targeting the survival cascade of B-cells in lymphoid malignancies

Wyndham Wilson, MD, PhD from the National Cancer Institute, Bethesda, MD talks about drugs that have been developed to indirectly target BCR, such as venetoclax (ABT-199), a Bcl-2 inhibitor; drugs targeting transcription factors, called bromodomain inhibitors, targeting MYC and NF-kappaB.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter